The Latest Pharmaceutical Trends Post Pandemic

???????The use of technologies had elevated steeply over the past years

???????The Covid-19 pandemic had enhanced this phenomenon

???????Mckinsey stipulates, the increase in e-commerce in the first half of 2020 is equivalent to that of the previous 10 years

????????Over two third of the costumers advise that they will continue to use the same omnichannel post pandemic

???????Zooming on the pharmaceutical sphere, robust growth is expected in the following technological related areas:

???????Virtual doctor consultation, electronic drug prescription, online purchasing of drugs, home self-test & diagnostic, wearable medical devices, online usage of professional forums and social networks groups

???????Technology will shape the patient behavior and manifest his futuristic experience

???????Profound usage of time, agile & remote work, less errors, and more computer orientation are expected

???????More accurate clinical trials prediction and design is expected due to the use of artificial intelligence and machine learning applicable tools

???????More competition is expected in the new drugs approval due to record drugs approvals

???????The oncology space is and will continue leading the new drugs development sphere with steady 40% market share of all the new drugs development programs

???????The bar of new drugs approval will be lifted, where curable disease and durable efficacy and safety will be part of the norm. Average to low drug’s efficacy and safety agents won’t be supported by the medical community and will be quickly replaced with more efficacious treatments in an ever-competitive environment?

???????Orphan drugs will continue to hold a big chunk of the drug developments, representing 40% of the new drugs approvals. This trend will continue to grow as merely 8% of the orphan drugs have a valid treatment

???????Going virtual trend expected to slow down, as more people are looking to socialized with others, and visiting their doctor, augmenting the gaps that was created pre and during the pandemic

???????More infectious viral disease is expected to merge, with the globalization, raising trends in the habitant immune deficiency, global warming and emerging Covid-19 variant and mutations

???????Patient centric approach need to be embraced rigorously, as patients become more knowledgeable on their medical conditions and the latest treatments to treat their condition

???????Companies should start to embrace holistic approach, rather than a product approach, where understanding the patient journey and needs should be main goal

???????Securing a collaboration to secure the above-mentioned strategies is of a vital importance, and could stimulate the performance of a given drug beyond the company expectations

???????Companies should perform strength and weakness analysis for the readiness for the digital technologies’ era??

?